newsfilter
← Latest News
ACCESS Newswire·

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

1.0% Formulation Reached Primary Endpoint with Statistical SignificanceFull Analysis Identified Additional Efficacy SignalsTORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. , a